As of September 30, 2026, Korsana Biosciences, Inc. carries a market capitalization of 1.46B, placing it among publicly traded companies globally. Its enterprise value stands at 1.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.46B |
| Enterprise Value | 1.00B |
Korsana Biosciences, Inc.'s next confirmed earnings release is scheduled for March 24, 2027.
| Earnings Date | 3/24/2027 |
As of September 30, 2026, Korsana Biosciences, Inc. has 45.54M shares outstanding.
| Shares Outstanding | 45.54M |
These figures are as of September 30, 2026.
| PB Ratio | 3.72 |
| P/TBV Ratio | 3.72 |
As of September 30, 2026, Korsana Biosciences, Inc. maintains a current ratio of 10.42, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.42 |
| Quick Ratio | 10.32 |
| Debt / Equity | 0.32 |
These figures cover the twelve months ended September 30, 2026.
| Employee Count | 1.00 |
As of the close on November 16, 2026, Korsana Biosciences, Inc.'s stock has gained approximately 243.28% over the past 52 weeks. The 50-day moving average sits at 54.23, while the 200-day moving average is 28.78.
| 52-Week Price Change | 243.28% |
| 50-Day Moving Average | 54.23 |
| 200-Day Moving Average | 28.78 |
As of September 30, 2026, Korsana Biosciences, Inc. holds 456.22M in cash and equivalents against 1.27M in total debt, resulting in a net debt position of -456.22M. Total book value stands at 391.56M, with working capital of 416.45M providing operational flexibility.
| Cash & Cash Equivalents | 456.22M |
| Total Debt | 1.27M |
| Net Debt | -456.22M |
| Equity (Book Value) | 391.56M |
| Book Value Per Share | 8.60 |
| Working Capital | 416.45M |
Korsana Biosciences, Inc.'s most recent stock split took place on September 9, 2026 with a 7:1 split ratio.
| Last Split Date | 9/9/2026 |
| Split Ratio | 7:1 |